Many lives of KATs - detector, integrator and modulator of cellular environment by Sheikh, B. & Akhtar, A.
Cells are presented with an ever- changing environment. 
During development, cells must detect molecular sig-
nals and gradients, modify their phenotype in response 
and subsequently remember those changes throughout 
life. Furthermore, differentiated cells are continuously 
exposed to stresses such as DNA damage, temperature 
fluctuations and changes in the availability of nutrients. 
To maintain cellular homeostasis, cells must mount 
an appropriate response to these challenges. One key 
mechanism governing the ability of cells to respond to 
intracellular and extracellular signals is the evolution-
ary conserved ε- lysine acetylation. This widespread and 
reversible post- translational modification is found on 
proteins throughout the cell and is particularly enriched 
on chromatin (Fig. 1a).
Levels of ε- lysine acetylation are closely controlled by 
the activity of lysine acetyltransferases (KATs) and lysine 
deacetylases (KDACs; also referred to as HDACs)1. 
KATs, a highly diverse group of enzymes, transfer 
the acetyl moiety from acetyl- CoA to lysine residues, 
whereas KDACs remove these marks. To date, 37 mam-
malian proteins have been suggested to possess endog-
enous KAT activity (Box 1). In this Review, we focus on 
the three best studied KAT families: the MYST family, 
named for its founding members MOZ (also known as 
KAT6A or MYST3), yeast Ybf2, Sas2, and Tip60 (also 
known as KAT5); the p300 (encoded by EP300) and CBP 
(also known as CREBBP) family; and the GCN5 (also 
known as KAT2A) and PCAF (also known as KAT2B) 
family. The enzymatic activity of these families has been 
well characterized and their biological functions are 
widely studied.
More than two decades ago, HAT1 (reF.2) and GCN5 
(reF3,4) were the first proteins found to possess KAT 
activity. Since these first reports, the importance of KATs 
for the regulation of transcription at the level of chroma-
tin has been studied comprehensively. Most KATs act at 
a unique subset of enhancer and promoter elements as 
well as in gene bodies of transcriptionally active genes to 
modulate the transcriptional output required for proper 
development and housekeeping functions1,5–7. KATs 
do not act alone; they are found in unique molecular 
complexes8–12 (Fig. 1b–h) that bestow upon KATs target 
specificity as well as the abilities to interact with a range 
of other proteins and to detect post- translational pro-
tein modifications. Importantly, KATs and their cata-
lytic activity are not just confined to chromatin13. Over 
2,000 acetylation targets, including nuclear, cytoplasmic, 
mitochondrial, endoplasmic reticulum and peroxisomal 
proteins, have been identified14. Acetylation can have a 
range of effects on target proteins, ranging from changes 
in cellular localization15–17 to modulation of enzymatic 
activity18 and their ability to interact with other protein 
complexes19,20. Furthermore, the catalytic activity and 
cellular localization of KATs themselves can be regulated 
by post- translational modifications, such as phosphoryl-
ation21 and acetylation22–25, and through the availability 
of key metabolites such as acetyl- CoA26–28.
Evidently, many cellular factors can both modulate 
and be regulated by KATs, making lysine acetylation 
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a candidate nexus for intracellular communication. 
Indeed, extensive research over the past decade has 
revealed protein acetylation to lie at the heart of cell sig-
nalling cascades regulating embryonic development29,30, 
stress response21,31, metabolism32,33 and diseases such as 
neurological disorders34 and cancer35. In this Review, we 
summarize the roles of KATs in regulating transcription 
and discuss the importance of KATs and their molec-
ular complexes as key detectors of cellular signals and 
environment. We deliberate how KATs and their com-
plexes integrate developmental and environmental sig-
nals to modulate the cellular phenotype. We highlight 
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developmental disorders and cancers that arise owing to 
mutations in KATs and outline the exciting avenues of 
future research that will provide important insights into 
the function of KATs in health and disease.
KATs as transcriptional regulators
A key feature of chromatin- associated KATs is their ability 
to modulate gene transcription. Acetylation of specific his-
tone residues, such as histone 4 lysine 16 (H4K16ac), can 
disrupt interactions between neighbouring nucleosomes as 
well as between histones and DNA, leading to the relax-
ation of chromatin structure and a more conducive envi-
ronment for transcription36–38. Similarly, modifications 
such as H3K27ac are associated with increased release 
of RNA polymerase II (Pol II) into active transcription39. 
Histone acetylation is also able to recruit proteins con-
taining the acetyl- binding bromodomain40,41, which is 
found in 42 different proteins in humans42 that span a 
range of chromatin complexes with the ability to further 
modify the chromatin environment. Furthermore, KATs 
directly acetylate a range of transcription factors, such 
as C/EBPα43, FOXO1 (reF.44) and the tumour suppressor 
p53 (reFs45–47), resulting in the modulation of transcrip-
tion factor activity and, subsequently, cellular home-
ostasis. Thus, KATs act on many levels in combination 
with other chromatin- modifying proteins to fine- tune 
transcriptional output from target loci.
Unique chromatin addresses for KATs
Individual KATs and their complexes are recruited in a 
context- specific and cell type- specific manner to par-
ticular genomic elements that can be broadly separated 
into promoters, enhancers and gene bodies. Each of these 
elements shows distinct histone acetylation patterns48  
and binding of KATs.
Active promoters are highly acetylated. Promoters of 
transcriptionally active genes are highly enriched in his-
tone acetylation49, particularly H3K9ac48,49, H2AK9ac49 
and H3K56ac48. Consistently, a number of KATs, such 
as MOF (also known as KAT8 or MYST1)5,50, GCN5 
(reFs29,51) and the MOZ–ING5 complex30,52,53, localize 
to promoter regions of their target loci; the presence 
of these KATs correlates positively with transcriptional 
activation, whereas their removal leads to reduced 
mRNA output from target loci. In addition to KATs, 
KDACs also localize to promoters of transcriptionally 
active genes and modulate acetylation levels to fine- tune 
transcriptional output1,54. Indeed, treatment of T cells 
with KDAC inhibitors increases recruitment of Pol 
II and transcription1, further underpinning the close 
relationship between KATs and KDACs in regulating 
acetylation and transcriptional output at active gene loci.
In addition to regulating transcription from anno-
tated promoters, work in the yeast Saccharomyces cer-
evisiae has uncovered the importance of chromatin 
structure in repressing cryptic transcription. During tran-
scriptional elongation, the Rpd3S KDAC complex is 
recruited to transcriptionally active gene bodies in an 
H3K36-methylation- dependent manner55. Deletion of 
Rpd3S complex members increases acetylation through-
out the gene body in S. cerevisiae, resulting in transcription 
initiation from intragenic promoters and promoter- like 
elements that are normally repressed and silenced under 
wild- type conditions56,57. More recently, these find-
ings have been extended to human cells. Treatment of 
human cancer cell lines with KDAC inhibitors increases 
the production of cryptic transcripts, many of which pos-
sess protein- coding open reading frames58. Furthermore, 
KDAC inhibition increases transcription from trans-
posable elements, which has the potential to appear 
‘foreign’ to cells and thus induce an immune response. 
While the exact importance of cryptic transcription is a 
matter of debate, these studies highlight the role of his-
tone acetylation in ensuring that the proper promoter 
elements are selected for transcription initiation.
KATs at enhancers. Following recent advances in the 
annotation of the non- coding genome, nearly 1 million 
gene regulatory elements such as enhancers have been 
predicted in the human genome59. Enhancers have cru-
cial roles during embryonic development, where they 
drive the transcription of multiple, developmentally 
important genes in a cell type- specific manner60–62. 
Through chromosome conformation capture techniques, 
it is now well established that interactions between 
enhancers and promoters are essential for coordinating 
transcription63–65 (Fig. 2).
Active enhancer–promoter pairs are highly enriched 
in acetylation marks such as H3K27ac62. Studies uti-
lizing chromatin immunoprecipitation (ChIP) and high- 
throughput sequencing have shown that the KATs p300 
and CBP, which share an identical and highly conserved 
domain structure, locate to active enhancers6,60,66. Both 
p300 and CBP, which do not have defined molecular com-
plexes, interact with and potentially acetylate hundreds 
of proteins, particularly transcription factors and chro-
matin remodellers67,68. Transcription factors are thought 
to recruit p300 and CBP to enhancer and promoter ele-
ments, thereby enabling p300 and CBP to activate tran-
scription at their target loci; for example, p53 recruits 
Fig. 1 | Mammalian KAT complexes. a | Acetylation sites on the four core histones — 
histone H2A , H2B, H3 and H4 — as mapped by global mass spectrometry analyses. 
Other types of post- translational modifications such as methylation and ubiquitylation 
can also occur at many of these lysine residues. b–h | Depiction of the major lysine 
acetyltransferase (KAT) complexes: MOZ/KAT6B–ING5 (part b), HBO1–JADE (part c), 
TIP60 (part d), MOF–NSL (part e), MOF–MSL (part f), GCN5/PCAF–SAGA (part g) and 
GCN5/PCAF–ATAC (part h), which contains two KATs. Domains that mediate interactions 
with other proteins or histone residues, including bromodomains, chromodomains,  
zinc- fingers, PWWP, tudor, WD40 and YEATS domains, are indicated in the respective 
complex members. These domains allow crosstalk between chromatin complexes and 
permit a coordinated response to maintain cellular functions. Furthermore, they bestow 
specificity upon complexes in vivo. Where possible, the interacting partner for each 
domain of the KAT complex is listed. The MOF chromobarrel domain has been shown to 
interact with RNA as part of the Drosophila melanogaster MSL complex to date242,243.  
ac, acetylated; bu, butyrylated; cr, crotonylated; ERα, oestrogen receptor- α; MCM2,  
mini- chromosome maintenance protein 2; me, methylated; N- term, amino terminal;  
pr, propionylated; su, succinylated; TRIP- Br, transcriptional regulator interacting with the 
PHD–bromodomain proteins; un, unmodified. Information on interaction partners was 
obtained from the following references: MOZ95,240,244, ING5 (reF.245), BRPF proteins241,246–250, 
HBO1 (reF.251), JADE proteins74, TIP60 (reFs252,253), MRG15 (reF.254), ING3 (reF.255), BRD8 
(reF.241), MOF256,257, PHF20 (reFs258–260), MSL3 (reF.81), GCN5 and PCAF241,261,262, SGF29 
(reF.263), STAF29 (reF.264), YEATS2 (reF.265) and YEATS4 (reFs93,94,266). KAT complex 
constituents were described by: MOZ/KAT6B–ING58, HBO1–JADE8, TIP60267, MOF–NSL9, 
MOF–MSL9, SAGA11 and ATAC12,268,269.
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Most basic units of chromatin. 
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Box 1 | Bona fide KATs
Although 37 human proteins have been reported to possess lysine acetyltransferase (KAT) activity (see the figure), only 
a proportion of these have been convincingly demonstrated to be KATs. In addition to the well- established KATs of the 
mYST, p300/CBP and GCN5 families, ATAT1 specifically acetylates microtubules at the K40 residue of α- tubulin181,182, 
which helps stabilize microtubules183. ESCO1 and ESCO2 acetylate the SMC3 subunit of the cohesin complex184.  
SmC3 acetylation is critical for sister chromatid cohesion during the S phase of mitosis and is conserved from humans184,185 
to yeast185–187. By contrast, despite weak evidence for endogenous KAT activity in vivo, a number of proteins continue to be 
categorized as KATs for historical reasons. For instance, the nuclear receptor co- activators NCOA1 (reF.188) and NCoA3 
(reF.189) isolated from cell lysates possess KAT activity in extracellular assays. However, numerous studies have also 
shown that NCOA1 and NCOA3 bind to other KATs, including CBP189–191, p300 (reFs189,191,192), GCN5 (reF.193) and PCAF189, 
via their activation domain, an interaction that is critical for the transcriptional activation mediated by NCoA190.  
Thus, it is likely that NCOAs primarily regulate transcription by bridging nuclear receptors to KATs rather than 
possessing endogenous KAT activity themselves. Similarly, the largest subunit of the general transcription factor TFIID 
complex TAF1 (reF.194), as well as three subunits of the TFIIIC complex, were shown to possess histone acetylation 
activity in extracellular assays195,196. However, little supporting evidence for their in vivo KAT activity has been 
forthcoming in the 20 years since these initial reports, and their catalytic mechanisms remain undetermined. 
Independent reports have also shown that the catalytic subunit of the elongator complex, ELP3, possesses KAT 
activity197–200. However, on the basis of recent work, primarily in the yeast Saccharomyces cerevisiae, consensus is 
building that ELP3 is likely to primarily modify uridines in the wobble base position of tRNAs201–203, a function that is 
supported by structural analysis204. This step requires the acetyltransferase activity of ELP3 and is conserved from 
archaea to yeast and humans205–207. Whereas BLOC1S1 possesses an acetyl- CoA binding domain, and modulation of 
BloC1S1 levels affects acetylation levels in the mitochondria208,209, this protein lacks a definable catalytic KAT domain. 
Furthermore, the KAT activity of some proteins is controversial owing to conflicting reports or the small number of 
publications addressing their KAT function to date. For instance, a number of reports have documented that NAA10 
acetylates lysine residues in HIF1α210, RuNX2 (reF.211), PGK1 (reF.212), HSP70 (reF.213), SAMHD1 (reF.214) and mSRA215. 
However, other investigations utilizing biochemical techniques and structural comparisons have argued against the 
KAT activity of NAA10 (reFs216,217). Similarly, only limited reports are available that demonstrate the KAT function of 
NAA50 (reFs218,219), NAA60 (reF.220) and BRD4 (reF.221) and of the metabolic enzymes ACAT1 (reF.222), ACAT2 (reF.223) 
and DLAT223. Thus, further investigations are required to determine whether any of these poorly characterized proteins 
purported to have KAT activity are in fact bona fide KATs.
Amino acid sequences for human KATs were used as the basis of the phylogenetic tree (see the figure). The tree was 
generated using the T- Coffee alignment algorithm224 and assembled using iTol225. The most common name for each KAT 
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p300 and CBP to its target loci in response to DNA dam-
age to activate transcription69,70. Following recruitment, 
p300 and CBP mediate the acetylation of H3K18 and 
H3K27 (reF.71), which is thought to stimulate Pol II to 
leave the promoter and start transcriptional elongation39.
Given that enhancers are active in a tissue- specific 
manner during development6, a key question facing 
the field has been how the activity of p300 and CBP at 
active enhancers is regulated. Recent work has reported 
that CBP can bind enhancer rNAs (eRNAs) via its cata-
lytic HAT domain, which in turn augments the catalytic 
activity of CBP towards H3K18 and H3K27, leading to 
the establishment of an active enhancer state72. However, 
depletion of eRNAs affects only the catalytic activity 
but not the recruitment of CBP, suggesting that CBP is 
recruited to enhancer elements by another mechanism72, 
most likely through interaction with transcription factors 
or other chromatin- associated proteins (Fig. 2). Although 
this report provides an exciting insight into the workings 
of CBP, future work is required to better understand the 
importance of this phenomenon in biological systems.
Transcription- permissive gene body. In addition to 
enhancer and promoter elements, which are critical for 
assembling and activating the transcription machinery, 
the main body of genes must also be kept in an open and 
transcriptionally permissive state to allow for the pas-
sage of Pol II. Gene bodies tend to be enriched for spe-
cific acetylation marks, including H2AK5ac, H2BK5ac, 
H3K14ac and H3K23ac48, as well as the GCN5–SAGA 
complex51. Although there are only limited mechanis-
tic data on the GCN5–SAGA complex in mammalian 
cells, studies in yeast have shown that, following tran-
scriptional activation, GCN5–SAGA mediates H3 
acetylation throughout the gene body and is important 
for eviction of nucleosomes during transcription51. 
Similarly, H3K14ac shows only minor enrichment at 
the promoter and instead is spread throughout the gene 
body49. Genome- wide H3K14 acetylation is mediated 
by HBO1 (also known as KAT7), as Hbo1 deletion in 
mouse models leads to complete loss of H3K14ac73. 
Biochemical studies have shown that HBO1 can acetylate 
histones throughout the gene body as well as promoters74. 
Enhancer RNAs
(erNAs). rNAs produced from 



































Fig. 2 | Transcriptional regulation by KAT complexes at chromatin. The presence of lysine acetyltransferase (KAT) 
complexes at chromatin is normally associated with a transcriptionally active state. p300 and CBP acetylate H2B, H3K18 
and H3K27 at active enhancers as well as promoters. MOF mediates the acetylation of H4K16 at promoters. MOZ and 
KAT6B are thought to mediate H3K9 and H3K23 acetylation, whereas GCN5 and PCAF catalyse H3K9 at promoters of 
transcriptionally active genes. In gene bodies, however, GCN5 and PCAF are thought to further acetylate H3 whereas 
HBO1 acetylates H3K14. Depending on the precise composition of its complex, HBO1 can also localize to promoters.  
In addition to histones, KATs acetylate a number of transcription factors (TFs) and inhibitors as well as transcription initiating 
complexes (for example, mediator) and chromatin remodellers (for example, cohesin). These have been particularly well 
mapped for p300 and CBP. The underlying effect of acetylation on TFs is highly TF- dependent as acetylation activates 
some TFs to promote transcription, whereas in other cases TFs are removed from chromatin. In addition, transcription and 
production of enhancer RNAs (eRNAs) from active enhancer elements stimulate the catalytic activity of CBP, leading to 
increased acetylation in CBP- associated chromatin regions. ac, acetylation; Pol II, RNA polymerase II.
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The preference of HBO1 for the gene body versus the 
promoter is believed to depend on the precise molecu-
lar composition of the HBO1 complex74, suggesting that 
further, unidentified KAT subcomplexes with unique 
chromatin targets may exist.
Whereas histone acetylation is generally associ-
ated with a transcriptionally active state, H4K20ac has 
recently been suggested to be involved in transcriptional 
repression. H4K20ac is enriched at promoters of lowly 
expressed genes75. Furthermore, strongly expressed genes 
do not show a promoter peak of H4K20ac but rather 
display increased enrichment towards the 3ʹ end. Motif 
analysis revealed that unlike other well- studied histone 
acetylation marks, H4K20ac did not overlap with binding 
of factors that promote transcription but is rather associ-
ated with the repressive mammalian REST (also known as 
NRSF) complex75. The importance of this mark remains 
to be determined as, paradoxically, bromodomains from 
CBP and PCAF can bind to H4K20ac peptides in vitro76,77 
and might thus possibly recruit these transcriptional 
activators to H4K20-acetylated chromatin. In addition 
to acetylation, the H4K20 residue can also be methyl-
ated. In contrast to H4K20ac, the H4K20 monomethyl-
ation (H4K20me1) is enriched in active gene bodies78,79. 
Structural studies have revealed that H4K20me1 binds 
strongly to the chromodomain of MSL3 (reFs80,81), a mem-
ber of the MOF–MSL complex that catalyses H4K16ac 
and promotes transcription5,9. However, the crosstalk 
between H4K16ac and H4K20 modifications is rather 
complicated, as acetylation of H4K16 abolishes the ability 
of the MSL3 chromodomain to bind H4K20me1 (reF.81). 
This mechanism may allow the MSL complex to ‘walk’ 
along large stretches of chromatin, such as the male X 
chromosome in Drosophila melanogaster, and acetylate 
target domains of chromatin. Thus, although the inter-
play of the histone modifications at the N- terminus 
of histone H4 in gene bodies seems critical for tran-
scriptional control, further work is required to clarify 
the precise mechanism through which it functions.
Crosstalk between chromatin complexes
Each KAT complex does not work in isolation but 
rather collaborates with other chromatin- modifying 
complexes. The crosstalk is mediated by domains found 
in chromatin complexes that are able to read specific 
combinations of histone modifications82. These include 
bromodomains83 and YEATS domains84, which detect 
acetylated residues, as well as chromodomains85, BAH 
domains86, tudor domains87, MBT domains87 and 
some PHD fingers88–90, which detect methylated lysines. 
Importantly, reader domains occur in different com-
binations and show preference for different histone 
modifications, adding specificity to KAT complexes 
(Fig. 1b–h). Thus, reader domains likely enable the 
sequential recruitment of chromatin complexes, leading 
to a complex hierarchy.
The interplay between complexes is best typified by 
H3K4 methylation, a mark catalysed by the MLL fam-
ily of proteins and read by an array of KAT complexes. 
MLL (also known as KMT2A) and H3K4 methylation 
are associated with promoters of transcriptionally 
active genes. Complexes that contain MOZ, KAT6B 
(also known as MORF or MYST4), HBO1, TIP60, 
MOF–NSL, GCN5 or PCAF all contain chromo-
domains or tudor domains that show affinity for the 
H3K4 dimethylation (H3K4me2) and/or trimethylation 
(H3K4me3) mark (Fig. 1b–h). Consistently, MLL medi-
ates the recruitment of MOZ to HOX loci and subse-
quent upregulation of HOX gene expression in human 
haematopoietic progenitor cells91. Similarly, MLL and 
MOF have been shown to interact and regulate the 
expression of Hoxa9 in fibroblasts, as depletion of MLL 
leads to a reduction of MOF- mediated H4K16ac and 
reduced Hoxa9 mRNA levels92.
Another interesting example is the YEATS domain of 
YEATS4, a member of the TIP60 complex (also known 
as the NuA4 complex) (Fig. 1d). YEATS4 shows affinity 
for acetylated H3K14 and H3K27 residues93,94 but binds 
with even higher affinity to histone tails that show dual 
acetylation at H3K18 and H3K27 or at H3K23 and 
H3K27 (reF.93). Similarly, the PHD fingers of MOZ show 
specificity for the combination of unmodified H3R2 
and acetylated H3K14 (reF.95). These studies suggest that 
some ‘reader’ domains are also able to read combinato-
rial histone modifications, enabling increased specificity 
in the crosstalk between chromatin complexes.
Although there is accumulating evidence for crosstalk 
between chromatin complexes, very few combinations 
of post- translational modifications and their affinity 
for reader domains have been extensively mapped. Given 
that many KAT complexes are present at active gene 
promoters (Fig. 2), they are likely to interact and collabo-
rate to control transcription. Thus, more work is needed 
to fully appreciate specific and complex interactions 
between the array of post- translational modifications 
and chromatin- modifying complexes that together 
modulate transcription.
Context- specific transcriptional regulation
Each cell type requires different transcriptional pro-
grammes to maintain cellular phenotype and respond 
to environmental stresses. Consistently, a distinct set 
of transcription factors is expressed in each different 
cell type and only a specific set of enhancer elements 
is active60–62. Recent research using knockout mouse 
models has uncovered that KATs act in a highly 
context- specific and cell type- dependent manner. This 
observation is perhaps best exemplified by the MOZ–
ING5 complex (Fig. 1b), which is recruited to specific 
genomic loci in a developmental time point- specific 
and tissue- specific manner. The MOZ–ING5 complex 
regulates heart development by activating the expres-
sion of transcription factors Tbx1 and Tbx5, where it is 
thought to maintain normal levels of H3K9 acetylation 
and thereby transcription52. By contrast, during B cell 
development, MOZ maintains the proliferation of pro-
genitor cells by maintaining the expression of Meis1 and 
Hoxa9 (reF.53), whereas MOZ regulates aspects of T cell 
function through acetylation of the Cd8 locus and the 
Cd8 enhancer E8I (reF.96). Furthermore, during the pat-
terning of the developing embryo at gastrulation, MOZ 
is recruited to the Hox cluster in vivo and is required 
for the timely activation of Hox genes and thereby 
correct assignment of body segment identity30,97,98. 
Chromodomain
An ~50 amino acid protein 
domain that generally 
recognizes methylated lysines.
PHD fingers
Protein domain, generally 
50–80 amino acids in length, 
that binds to post- 
translationally modified lysine 
residues.
Gastrulation
Developmental phase during 
early embryogenesis in which 
the three major embryonic 
layers (endoderm, ectoderm 
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One common feature to emerge from this body of work 
is that MOZ tends to mediate the transcriptional activa-
tion of developmentally important transcription factors, 
which may lie at the top of the hierarchy specifying cell 
fate. However, it remains to be established how MOZ 
is recruited to these loci in a context- specific manner.
Recent findings from the acetylome of p300 and CBP 
also support the view that chromatin targets of KATs 
depend on cell type and context. Whereas inhibition 
of p300 and CBP or genetic deletion of their encod-
ing genes in mouse embryonic fibroblasts led to the 
reduction of lysine acetylation at hundreds of sites on 
histones and transcription factors, the resulting tran-
scriptional changes were fairly minor67. This finding 
may suggest that acetylation primes cells to respond 
to external stimuli. Thus, defects in cells lacking KAT 
activity might be evident only in the presence of specific 
stresses. Accordingly, work on MOF in kidney podocytes 
has shown that MOF is dispensable for kidney function 
at steady state; however, a mild stress induces breakdown 
of podocytes lacking MOF and results in kidney failure31. 
More work is needed to fully understand under which 
conditions different KATs are critical for maintaining 
cellular homeostasis.
Detection and modulation of cellular milieu
Consistent with their role in transcriptional regulation, 
KATs are highly enriched in the nucleus. However, KATs 
and KDACs are also present in considerable quantities in 
the cytoplasm and in organelles such as the mitochon-
dria13. In accordance, over 2,000 proteins have been iden-
tified to possess at least one acetylated ε- lysine residue14. 
Given the breadth of ε- lysine acetylation present in cells, 
acetylation by KATs has been implicated in essentially all 
cellular processes. While these processes are too numer-
ous to cover here, we highlight below novel and exciting 
findings showing that KATs act at the interface of the 
environment and gene regulation.
Interplay between metabolism and acetylation. The 
acetyl donor for KATs, acetyl- CoA, also serves as a key 
metabolite in the tricarboxylic acid (TCA) cycle and as the 
basic building block for lipids99,100. This dual role of acetyl- 
CoA, as a donor for acetylation and a central metabo-
lite, suggests a potential link between metabolism and 
modulation of cellular processes by acetylation. Levels 
of acetyl- CoA are highly susceptible to the availability of 
nutrients. In hearts and muscles of fasted animals, as 
well as in cells grown in nutrient- poor conditions, there 
is considerable depletion of cellular acetyl- CoA levels101. 
This reduction in acetyl- CoA levels correlates strongly 
with a global reduction in acetylation101.
There is now mounting evidence that local changes in 
acetyl- CoA levels can also modulate cellular functions. 
Enzymes that produce acetyl- CoA show dynamic intra-
cellular localization. Under cellular growth conditions 
in vitro, the pyruvate dehydrogenase complex (PDC), 
which converts pyruvate to acetyl- CoA, accumulates 
in the nucleus32. Similarly, ATP citrate lyase (ACL; also 
known as ACLY), which converts citrate to acetyl- CoA, 
has been detected in the nucleus33 (Fig. 3). Accordingly, 
depletion of ACL or PDC components from cells under 
growth conditions leads to a reduction in histone acetyl-
ation32,33. This temporal shift and local production of 
acetyl- CoA in the nucleus has also been observed during 
cellular differentiation. During neuronal differentiation, 
acetyl- CoA synthase short chain 2 (ACSS2), the enzyme 
converting acetate to acetyl- CoA, becomes nuclear, and 
its activity is required for the acetylation of histones at 
genes involved in neuronal differentiation and therefore 
their expression27. ACSS2 directly interacts with CBP, 
and inhibition of ACSS2 leads to a global reduction in 
H3K27ac. In accordance, knockdown of Acss2 in the 
mouse hippocampus, an area associated with memory and 
learning, results in reduced expression of neuronal mark-
ers and defects in spatial memory27. Further contributing 
to the crosstalk between metabolism and acetylation, the 
by- product of the acetylation reaction, CoA, competes 
against acetyl- CoA for binding to a range of KATs and 
thereby inhibits KAT activity102,103. Moreover, it is now 
apparent that KATs can also use other acyl- CoA mol-
ecules, such as succinyl- CoA and crotonyl- CoA, which 
also serve as metabolic intermediates, to modify ε- lysine 
residues (Box 2). Thus, cells can sense their metabolic 
environment through changes in central metabolites such 
as acetyl- CoA and respond via KATs to adjust the tran-
scriptional output of target loci and modify the catalytic 
activity of target enzymes (Fig. 3).
A number of studies have started to focus on the 
impact of metabolite- induced acetylation changes on 
transcription factors. Transcription factors regulating 
metabolic networks such as C/EBPα43, CRTC2 (reF.104), 
PGC1α105 and FXR106 (also known as BAR) are dynami-
cally regulated by acetylation. In the presence of high 
glucose, C/EBPα is acetylated by p300 in the transac-
tivation and DNA- binding domains43. However, in a 
fasted state, the KDAC SIRT1 deacetylates C/EBPα. 
The deacetylation of C/EBPα induces the expression of 
genes required for mitochondrial biogenesis, which in 
turn stimulates ATP production and thereby maintains 
cellular energy levels under low glucose conditions43. 
Similarly, GCN5-mediated acetylation of PGC1α, a 
transcription factor commonly dysregulated in diabetes 
mellitus, inhibits its activity under fed conditions105.
In addition to transcription factors, metabolic 
enzymes themselves are highly acetylated18, and lev-
els of acetylation have a strong effect on the activity 
of metabolic enzymes. For example, glucose promotes 
the acetylation of the TCA cycle enzyme MDH, which 
stimulates its activity18. By contrast, glucose- mediated 
acetylation of ASL, an enzyme that shuttles breakdown 
products of amino acids to the TCA cycle, leads to the 
inhibition of ASL18. Also consistent with a systemic 
response to nutrient availability, high glucose levels 
result in the p300-mediated acetylation and subsequent 
degradation of PEPCK1 (reF.107), an enzyme required for 
gluconeogenesis or production of glucose. Thus, cells 
can mount a well- coordinated response to changing 
nutrient levels through lysine acetylation.
As many of the acetylated metabolic enzymes are 
located in the mitochondria, researchers have been try-
ing to establish which KATs and KDACs localize to this 
organelle. Whereas many KDACs, including HDAC1 
(reF.108), HDAC7 (reF.109), SIRT3 (reF.110), SIRT4 (reF.111) 
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and SIRT5 (reF.111), are known to localize to the mito-
chondria, MOF was recently identified as the first bona 
fide KAT with mitochondrial localization in human 
HeLa cells112. Furthermore, when HeLa cells were cul-
tured in the presence of galactose but not glucose, con-
ditions that require cells to use mitochondrial respiration 
to generate ATP, MOF was required for progression 
of the mitochondrial RNA polymerase POLRMT through 
the mitochondrial genome and maintaining normal 
levels of transcription112. Future studies are required to 
determine the exact mechanism through which MOF 
regulates mitochondrial transcription, especially in non- 
cancerous cells. Nevertheless, these findings open the 
exciting possibility that cells may use MOF as a commu-
nication module between the mitochondria and nucleus 
to regulate the metabolic milieu. Consistent with this 
proposition, the KDAC SIRT3 is transported from the 
nucleus to the mitochondria under stress conditions113, 
where it has a critical role in responding to oxidative and 
metabolic stress114,115. Given recent advances in the sen-
sitivity of mass spectrometry instruments116 and proto-
cols for organelle isolation117, determining whether KATs 
display a dynamic shift in organellar localization during 
conditions of environmental or metabolic stress will be 
a promising avenue of research.
Cellular adaption to stress via autophagy and acetyla-
tion. In situations of stress, such as nutrient deprivation, 
cells activate autophagy, a comprehensive response that 
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Fig. 3 | Acetylation as a means of cellular communication. Acetyl- CoA within cells can be obtained from a number of 
sources. Within the mitochondria, fatty acids and amino acids can be broken down to give rise to acetyl- CoA. 
Furthermore, pyruvate derived from glucose can be converted into acetyl- CoA via the pyruvate dehydrogenase complex 
(PDC). Acetyl- CoA is subsequently used to acetylate mitochondrial proteins and is channelled into the tricarboxylic acid 
(TCA) cycle to generate energy. Via a citrate transporter, the TCA cycle intermediate citrate can be shunted from the 
mitochondria to the cytoplasm. Three major precursors of acetyl- CoA (pyruvate, acetate and citrate) can also diffuse into 
the nucleus, where they are processed into acetyl- CoA. Given that acetyl- CoA is generated from the step- wise 
breakdown of dietary energy sources, levels of acetyl- CoA are high in cells when nutrients are plentiful. These high levels 
of acetyl- CoA lead to increased acetylation within the cell at the level of mitochondrial, cytoplasmic and nuclear proteins 
as well as histones via lysine acetyltransferase (KAT)-dependent and KAT- independent mechanisms. This increased 
acetylation in turn leads to the activation of genes required for cellular growth and storage of energy in lipids. 
Concurrently , the gene networks required for autophagy are repressed. By contrast, under starvation conditions, cellular 
acetyl- CoA levels drop markedly , leading to reduced protein acetylation as well as activation of the NAD+-dependent 
lysine deacetylases (KDACs) of the SIRT family. Thus, the cell can sense its metabolic environment and use acetylation to 
regulate core cellular processes related to energy utilization and growth. Enzymes producing acetyl- CoA are listed in 
blue. Δ, change in; ac, acetylation; ACL , ATP citrate lyase; ACSS, acetyl- CoA synthase short chain; TF, transcription factor.
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to protect cells from damage118. The breakdown prod-
ucts are subsequently used to form new proteins as well 
as precursors for generating energy. Given the mod-
ulation of acetyl- CoA levels in a nutrient- dependent 
manner101, key components of autophagy are also regu-
lated by acetylation and KATs. In both yeast and fruitfly 
models, genetic modulation that reduces acetyl- CoA 
levels leads to decreased histone acetylation, induction 
of autophagy and increased organismal lifespan119.
In mammalian cells, autophagy correlates with 
reduced levels of p300 activity21, MOF and H4K16ac120. 
By contrast, when nutrients are present, MOF induces 
the expression of genes required for mitochondrial 
function and metabolism112. Similarly, in a fed state, 
p300 is phosphorylated and activated by mTOR com-
plex 1 (mTORC1)21, an inhibitor of autophagy. In turn, 
p300 acetylates the transcription factor SREBP-1c 
and induces the expression of genes required for lipo-
genesis, leading to the accumulation of intracellular 
fatty acids21. Concurrently, p300 is thought to acetylate 
and inhibit key components of the pro- autophagic 
response including LC3 (reF.121), ATG5, ATG7, ATG8 and 
Box 2 | Acylations catalysed by KATs
While lysine acetyltransferase (KAT)-mediated transfer of an acetyl group from the metabolic intermediate acetyl- CoA  
to ε- lysine residues has long been recognized as a post- translational modification, a number of similar acyl- chain 
modifications at ε- lysine residues (see the figure) have been identified more recently through mass spectrometry 
approaches. These include propionylation226, butyrylation226, crotonylation227, malonylation228 and succinylation228 and 
involve the transfer of the acyl chain from the respective CoA- bound molecule to lysine. The acyl- CoA molecules are also 
metabolic intermediates, suggesting that similar to acetyl- CoA they can serve as communication instruments within cells. 
While the transfer of acyl- CoA molecules can occur non- enzymatically in many instances229–232, particularly in organelles 
with a high pH such as the mitochondria230–232, there is increasing evidence that acyl marks can also be catalysed by KATs. 
CBP and p300 are reported to catalyse propionyalation226, butyrylation226 and crotonylation233,234, albeit with reduced 
efficiency compared with acetylation235. Similarly, MOF can reportedly catalyse propionyalation236 and crotonylation233, 
GCN5 can catalyse succinylation237, and moZ236, HBO1 (reF.236) and PCAF238 can catalyse propionylation. Recent structural 
studies of GCN5 have shown that the succinyl- CoA molecule binds to the same catalytic pocket as acetyl- CoA but buries 
deeper into the hydrophobic binding pocket237. Although these results await confirmation by independent groups, they 
nevertheless suggest that the catalytic mechanism for the transfer of acyl groups by KATs may be conserved. Similar to 
acetylation, the quantity of each acyl modification is dependent on the levels of the respective CoA intermediate present 
in cells234,239, leading to the hypothesis that lysine acylation may act as a cellular reservoir of energy while simultaneously 
informing the cell of its nutritional status. At the level of histones, the reported acylations are also related to a 
transcriptionally active state. Indeed, histone crotonylation233,234 and succinylation237 have been reported to promote 
transcriptional output. Further underpinning their importance, acylated lysine residues are detected by ‘reader’ domains, 
allowing crosstalk between chromatin complexes and potential recruitment of signalling molecules. For instance, 
structural and biochemical assays have shown that the PHD fingers of MOZ can bind to a range of acylations but show a 
particularly high affinity for H3K14 crotonylation both in vivo and in vitro240. Moreover, a recent screen testing the affinity 
of bromodomains for various acylations found that the majority of human bromodomains can bind to propionylated 
lysines241. However, the affinity of bromodomains for other acylations was rarer. Only bromodomains of BRD8, CECR2 
and TAF1 could recognize butyrylated lysines, whereas only the second TAF1 bromodomain could bind to crotonylated 
residues241. One limiting feature of this report could be that only the amino- terminal parts of histone H3 and H4 were 
analysed. Nevertheless, it is becoming clear that acylations other than acetylation can also be ‘read’ by proteins within 
the cell. Thus, given that the levels of acylations are based on the levels of the respective CoA metabolic intermediate, 
these modifications are reversible, they have a direct impact on transcriptional levels and they can be read by domains 
present in an array of chromatin complexes, they are likely to have an important physiological role in cellular processes. 
Further investigation of the importance of acylations will be an exciting avenue of research in the future.
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ATG12 (reF.122), particularly in the presence of nutrients. 
Accordingly, p300 depletion induces autophagy, whereas 
overexpression of p300 inhibits autophagy121,122. In con-
trast to p300 induction, autophagy induced by serum 
deprivation leads to association of the protein kinase 
GSK3β with TIP60 and subsequent phosphorylation 
at serine 86 of TIP60 (reF.123). Phosphorylated TIP60 
acetylates and activates ATG1 (also known as ULK1) 
and thus promotes autophagy. Thus, in addition to reg-
ulating metabolic networks, certain KATs are required 
to induce and maintain cellular homeostasis in the face 
of nutrient deprivation via autophagy.
Developmental signals induce phenotypic changes via 
KATs. Embryonic development requires the integration 
of both intracellular and extracellular signals to specify 
cell fate. Although there is a substantial body of data on 
the molecular role of KATs, fairly little is known about 
how these mechanistic functions are regulated in vivo. 
This regulation is particularly important, as mouse mod-
els deficient in any of the major KATs, including p300 
(reF.124), CBP125, MOZ126,127, MOF128, HBO1 (reF.73), TIP60 
(reF.129) and GCN5 (reF.130), show lethality at or before 
birth, suggesting a critical function of KATs during the 
developmental time frame. Furthermore, researchers 
have yet to fully appreciate the importance of the cata-
lytic versus scaffolding role of KATs. For example, 
although Gcn5 knockout mice begin to display extensive 
apoptosis and cell death from day 7 of gestation130, two- 
thirds of mice with a catalytically inactive GCN5 do not 
show increased apoptosis and survive until much later 
in gestation, albeit with defects in neural tube closure131.
A small number of studies have provided impor-
tant insights into mechanisms that drive development 
via KATs. The MOZ–ING5 complex30 as well as the 
GCN5–SAGA complex29 coordinate a subset of their 
activities with receptors for retinoic acid, a key cell- 
permeable morphogen that induces cell fates in the devel-
oping embryo132. Concordantly, depletion of MOZ30 or 
GCN5 (reF.133) leads to defects in the anterior–posterior 
patterning of the developing embryo. In addition, reti-
noic acid and GCN5 collaborate to correctly pattern the 
diencephalon in the developing brain. In the absence of 
retinoic acid, GCN5 along with the retinoic acid receptor 
RARα and TACC1 localize to specific genomic retinoic 
acid response elements29. In response to retinoic acid, 
GCN5 acetylates TACC1 and displaces it from chroma-
tin, leading to activation of retinoic acid target genes. 
Through this mechanism, GCN5 is thought to restrict 
sonic hedgehog signalling and correctly pattern the 
diencephalon29, a brain region often defective in neu-
ral developmental and psychiatric disorders. Consistent 
with the importance of GCN5 and MOZ in mediating 
retinoic acid signalling, administration of exogenous 
retinoic acid during embryogenesis can rescue the dien-
cephalon defects observed in animals with a catalytically 
dead GCN5 (reF.29) as well as the anterior–posterior 
patterning defects in Moz knockout30 animals. These 
studies provide important insights into how KAT com-
plexes coordinate their activity with morphogenetic 
signals during development to drive the transcriptional 
programmes required for cell identity specification.
KATs and disease
Given the importance of KATs as key mediators of cel-
lular homeostasis, their levels and activity are critical 
for human health. Mutations arising in KATs de novo 
during development give rise to severe human develop-
mental disorders, whereas a range of KAT mutations in 
adults give rise to malignancy.
KATs in developmental disorders. Mutations in the KAT 
genes CBP134, EP300 (reF.135), MOZ136,137, KAT6B138–142 and 
ESCO2 (reF.143) underlie human developmental disorders 
that are typified by developmental delay and intellectual 
disability. Apart from very exceptional cases, mutations 
in CBP134, EP300 (reF.135), MOZ136,137 and KAT6B138–142 
arise de novo and are dominant, whereas mutations 
in ESCO2 are inherited and recessive143. In addition to 
intellectual disability, a range of cardiac, craniofacial, 
genital and behavioural issues are associated with these 
disorders (Fig. 4). While intellectual disability is a hall-
mark observed in the majority of patients, one key fea-
ture of these disorders is phenotypic variability142,144–149. 
This observation is consistent with the fact that KATs 
lie at the interface between the environment and gene 
expression, and the disease phenotype is thus likely to 
be affected by environmental factors.
A second notable feature of these syndromes is 
that the catalytic activity of KATs is not always dis-
rupted136,144,146,148. Consistent with the requirement of 
KATs to collaborate with other proteins and molecular 
complexes, many of the truncations and deletions affect 
domains that are solely responsible for mediating pro-
tein–protein interactions. This finding is best typified 
by mutations in KAT6B, which have been described 
in a range of phenotypically diverse but overlapping 
intellectual disability syndromes spanning Noonan- like 
syndrome141, Say–Barber–Biesecker syndrome139, genito-
patellar syndrome140,142 and blepharophimosis–ptosis– 
epicanthus inversus syndrome138. These seemingly dis-
parate syndromes show a strong overlap in their clinical 
presentation. Nevertheless, mutations in KAT6B that 
completely inactivate the protein, leading to haploin-
sufficiency, result in a milder phenotype than muta-
tions that truncate KAT6B at the start of the last exon 
and thereby leave the catalytic acetyltransferase domain 
intact144,146,150. The phenotypic severity also tends to 
be milder in truncations that are further towards the 
C- terminus of the serine- and methionine- rich domain of 
KAT6B144, which is encoded by the last exon. Similarly, 
although only 11 patients with MOZ mutations have 
been reported, clinicians noted that 1 patient with a 
heterozygous deletion of MOZ had a milder phenotype 
than individuals with truncations at the C- terminus of 
MOZ136. This carboxy- terminal domain of KAT6B and 
MOZ is highly conserved and has been shown to interact 
with transcription factors such as RUNX1 and RUNX2 
(reF.151). These observations suggest that the ability of 
KAT complexes to interact with partner proteins and 
detect other post- translational modifications is crucial 
to their function. This conclusion is further underscored 
by the fact that mutations in genes encoding KAT com-
plex members such as KANSL1 (reFs152,153) and KANSL2 
(reF.154) from the MOF–NSL complex, MSL3 (reF.155) from 
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the MOF–MSL complex and BRPF1 (reF.156), the prod-
uct of which interacts with MOZ, KAT6B and HBO1 
complexes8, also lead to intellectual disability syndromes.
Comparing the KANSL1-mediated Koolen de Vries 
syndrome and the MSL3 syndrome is particularly inter-
esting, as KANSL1 and MSL3 belong to two different 
complexes but use MOF as their catalytic subunit10. While 
patients with mutations in either gene display intellectual 
disability, the facial dysmorphisms in each syndrome are 
unique155,157. Furthermore, patients with Koolen de Vries 
syndrome display general muscle weakness157, whereas 
patients with MSL3 syndrome display a progressive dis-
turbance in gait155. One characteristic feature of Koolen 
de Vries syndrome is the friendly and sociable behaviour 
of patients157, which has not been reported for patients 
with the MSL3 syndrome. Other reported phenotypes of 
Koolen de Vries syndrome that have not been reported 
for the MSL3 syndrome are seizures and defects in brain 
morphology, including abnormal hippocampi, dilated 
ventricles and corpus callosum dysgenesis157,158. Thus, it is 
apparent that the MSL and NSL complexes, which use 
the same KAT as their catalytic unit, are likely to target 
distinct gene loci and cellular proteins to mediate proper 
neural development and function. The relationship 
between the two complexes and their unique roles in the 
context of MOF still need to be fully characterized.
Regardless of whether the mutations underlying 
intellectual disability disrupt the KAT domain or solely 
protein- interaction domains, reductions in acetyla-
tion levels have been described in the CBP- disrupted 
Rubinstein–Taybi syndrome159 and in intellectual dis-
ability disorders associated with mutations in MOZ137 
or KAT6B140. Similarly, mutations in the MOF–MSL 
complex member MSL3 result in the reduction of MOF- 
mediated H4K16ac155. Given that KDACs are also present 
at KAT target loci and maintain the balance of acetyla-
tion1, one plausible therapeutic option is treatment with 
KDAC inhibitors. Indeed, administering KDAC inhib-
itors in animal models improves cognitive function, in 
particular memory function160,161. Concordantly, KDAC 
inhibitors have shown promise in mouse models of 
Rubinstein–Taybi syndrome162. Whether KDAC inhib-
itors will be effective in patients with intellectual dis-
ability remains to be established, especially since changes 
in KAT activity can have adverse effects such as cancer.
KAT mutations driving cancer. Consistent with the 
importance of acetylation levels in cells, somatic muta-
tions in KATs lead to malignancy. Whether KATs act 
as tumour suppressors or oncogenes is largely context- 
specific and depends on the specific type of cancer and 
mutation (TABle 1). In general, translocations involv-
ing one or more KATs, such as MOZ–NCOA2, bestow 
pro- tumorigenic characteristics, including increased 
self- renewal on progenitor cells163. In accordance, the 
MOZ–NCOA2 fusion protein is able to supress expres-
sion of the Cdkn2a locus and thus cellular senescence164. 
A recent screen across a spectrum of different malig-
nancies for changes in copy number variations iden-
tified MOZ as one of the most significantly amplified 
loci across an array of cancers165. Along with work on 
MOZ- translocation proteins, this study suggests that 
the aberrant activity of MOZ is particularly important 
in promoting the oncogenic state. In agreement, work in 
mouse models has shown that MOZ supresses cellular 
senescence, promotes proliferation of progenitor cells 
and maintains stem cell self- renewal166–168. By contrast, 
pro- tumorigenic mutations in CBP, EP300 and TIP60 
tend to be inactivating mutations (TABle 1), suggesting 
that they act as tumour suppressors.
In addition to mutations in KATs, dysregulation 
of KAT protein levels and their catalytic activity also 
drive carcinogenesis. In a screen for changes in chro-
matin modifications across a panel of cancers, reduced 
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Fig. 4 | Phenotypic abnormalities in KAT- associated developmental syndromes. 
Mutations in at least five lysine acetyltransferase (KAT) genes (CBP, EP300, KAT6B,  
MOZ and ESCO2) in humans lead to developmental disorders typified by intellectual 
disability and developmental delay. Depending on the precise locality of mutations  
in KAT6B, the associated abnormalities vary , leading to the designation of at least  
two different syndromes; genitopatellar syndrome (GPS) and Say–Barber–Biesecker 
syndrome (SBBS). The heat map represents and compares the major neurological, 
craniofacial, skeletal and other common phenotypes associated with KAT- related 
developmental syndromes. Despite the syndromes all being typified by intellectual 
disability and developmental delay , other abnormalities occur at different frequencies in 
each syndrome, which correlates with the unique protein and genomic targets of each 
respective KAT. In cases in which a given abnormality has not been detected or reported, 
its occurrence was taken as zero. Data were collated from reFs136,137,139,142,144,147,149,270–273. 
RBS, Robert syndrome; RTS, Rubinstein–Taybi syndrome.
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frequent changes169. Accordingly, a number of more 
recent studies have established that the KAT responsible 
for H4K16ac, MOF, is expressed at low levels in a range 
of cancers, including breast170, ovarian171, colorectal172, 
renal172, gastric172,173 and hepatocellular cancers174. Similar 
to H4K16ac, low MOF levels correlate with poor prog-
nosis and increased metastasis170–174. The significance of 
low H4K16ac and MOF levels in cancer remains to be 
determined as, counterintuitively, MOF is required for 
cell proliferation in mammalian cell culture systems31.
Given the changes in KAT activity and acetylation 
levels in tumours, modulation of KAT complex activ-
ity is a viable target for the development of anticancer 
therapies. KATs have traditionally been challenging 
targets for small- molecule inhibition. Until recently, the 
majority of described inhibitors displayed an array of 
undesirable properties, such as off- target activity, which 
rendered them inadequate as specific modulators of 
KAT activity175,176. In the past year, however, selective 
and highly potent inhibitors against p300 and CBP 
(A-485)177 as well as MOZ and KAT6B (WM-8014 and 
WM-1119)178 have been developed. Structural studies 
have shown that these inhibitors bind directly to the 
acetyl- CoA-binding domain in the respective KAT177,178. 
The p300/CBP- specific inhibitor A-485 has been tested 
for efficacy against 124 different cell lines. Consistent 
with the context- specific roles of KATs, the response 
of tumours to A-485 varied, with haematological and 
androgen receptor (AR)-positive prostate tumours 
showing the strongest response. In a xenograft model 
of AR- positive prostate cancer, A-485 was able to signif-
icantly decrease tumour burden177. Similarly, WM-8014 
was able to induce cellular senescence without causing 
DNA damage in cell culture systems178, a phenotype con-
sistent with Moz deletion in primary cells166. Moreover, 
WM-8014 reduced tumour burden in a zebrafish model 
of RAS- V12-driven hepatocellular carcinoma. Similarly, 
treatment with WM-1119, which displays better bio-
availability than WM-8014 in vivo, was able to clear 
MYC- driven lymphoma burden in mouse models178. 
Table 1 | KAT mutations in cancer
Cancer Mutation Refs
Acute lymphoblastic leukaemia (relapse) CBP loss 274
Acute myeloid leukaemia KAT6B–CBP t(10;16)(q22;p13) translocations 275,276
Acute myeloid leukaemia MLL–CBP t(11;16)(q23;p13) translocations 277,278
Acute myeloid leukaemia MLL–EP300 t(11;22)(q23;q13) translocation 279
Acute myeloid leukaemia MOZ–CBP t(8;16)(p11;p13) translocations 280
Acute myeloid leukaemia MOZ–NCOA2 inv(8)(p11q13) rearrangement 281
Acute myeloid leukaemia MOZ–NCOA3 t(8;20)(p11;q13) translocations 282
Acute myeloid leukaemia MOZ–EP300 t(8;22)(p11;q13) translocations 276,283
Bladder cancer KAT6B deletion 165
Breast cancer EP300 in- frame insertions and frameshifts 284
Breast cancer CBP missense mutations 285
Breast cancer MOZ amplification 165
Breast cancer TIP60 heterozygous deletion 165,286
Colorectal cancer EP300 nonsense, missense and intronic mutations 284,287
Colorectal cancer KAT6B amplification 165
Oesophageal adenocarcinoma MOZ mutations 288
Gastric cancer EP300 inactivating mutations 287
Head and neck squamous cell carcinoma TIP60 heterozygous deletion 286
Leiomyoma, retroperitoneal KAT6B–KANSL1 t(10;17)(q22;q21) translocation 289
Leiomyoma, uterine KAT6B t(10;17) translocations 290
Lung adenocarcinoma MOZ amplification 165
Lung, small- cell lung carcinoma CBP and EP300 inactivating mutations 291
Lung, small- cell lung carcinoma KAT6B deletions 292
Lymphoma, diffuse large B cell CBP or EP300 heterozygous mutations 293
Lymphoma, follicular CBP or EP300 heterozygous mutations 293
Lymphoma, follicular TIP60 heterozygous deletion 286
Medulloblastoma (paediatric) MOZ amplification 294
Ovarian cancer CBP truncations and missense mutations 285
Ovarian cancer MOZ amplification 165
Uterine and/or cervical cancer MOZ amplification 165
KAT, lysine acetyltransferase.
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Thus, the development and preclinical analyses of these 
compounds hold promise for their potential use in a 
clinical setting.
In addition to KAT inhibitors, a range of KDAC 
inhibitors have been developed that lead to an increase 
in acetylation levels. KDAC inhibitors tend to act 
broadly and concurrently inhibit the activity of a range 
of KDACs179,180. KDAC inhibitors have shown promise 
as anticancer agents, albeit with mixed results, with the 
strongest efficacy observed against specific haemato-
poietic malignancies. Three KDAC inhibitors — SAHA 
(vorinostat) against cutaneous T cell lymphoma, belino-
stat against peripheral T cell lymphoma and panobino-
stat against multiple myeloma — are currently in clinical 
use, with a number of other KDAC inhibitors currently 
undergoing clinical trials.
From a large body of preclinical studies, it is evident 
that cancers do not simply display increased or decreased 
acetylation levels or KAT activity. Rather, changes in 
acetylation levels seem to be cancer- specific and cell 
type- specific. Thus, care is required when choosing 
acetylation modulators, especially KDAC versus KAT 
inhibitors, against a particular cancer type. The substan-
tial body of preclinical data from both human studies 
and mouse models should be used in developing these 
strategies. Nevertheless, both KAT and KDAC inhibitors 
and their further development provide a promising ave-
nue towards the development of acetylation modulators 
that are effective against a range of cancers.
Conclusions
ε- Lysine acetylation is a widespread post- translational 
modification that is catalysed by KATs. Although acetyl-
ation modulates a vast array of cellular functions, it 
seems to be particularly enriched on chromatin, meta-
bolic enzymes and transcriptional regulators14. Recent 
work is starting to reveal that KATs act at the interface 
of the cellular environment and transcription, and their 
activity is highly dependent on the cellular milieu. 
Indeed, by detecting levels of metabolic intermediates 
such as acetyl- CoA, KATs modify the levels of acetyla-
tion on target proteins and thereby allow cells to detect, 
respond and directly meet their homeostatic needs.
Despite the recent increase in our understanding 
of KATs, a number of important questions remain. 
Foremost, KAT complexes are recruited to specific 
genomic loci in a cell type- specific and environment- 
specific manner. How these complexes are recruited and 
what provides specificity in different cell types remains 
to be fully established. Recently, the acetylome of p300 
and CBP was reported, uncovering acetylation changes 
in hundreds of proteins related to transcription and 
chromatin67. This finding suggests that traditional bio-
chemical techniques used to probe interactions between 
KATs and their associated proteins may need to be revis-
ited, as many of the interactions are likely to be transient 
and substoichiometric in nature and found only in par-
ticular cell types. Accordingly, there is an urgent need 
to determine the protein targets of other KATs through 
the use of similar mass spectrometry- based techniques. 
Notwithstanding our increased understanding of KATs 
through structural and biochemical analyses as well 
as animal models, there remains a chasm between 
mechanistic analysis and their relevance in vivo both 
in organismal models and in specific cell types. Thus, 
how KATs mechanistically drive specific transcriptional 
programmes and signalling networks in development, in 
complex organs and under conditions of stress needs to 
be systematically studied in model organisms under the 
guidance of data collated from biochemical studies. The 
advent and spread of the CRISPR technology, the con-
tinuous growth of animal repositories with conditional 
knockout mouse models and the widespread use of 
single- cell genomics will undoubtedly help in addressing 
these important questions.
Since the discovery of the first KAT around two dec-
ades ago2, we have come a long way in understanding the 
enigma of KATs. Further research probing KAT func-
tion in health and disease through a combination of bio-
chemical and organismal models will allow us to have a 
better understanding of how cells control homeostasis 
and respond to changing conditions. The continuous 
development of potent small- molecule modulators of 
KAT activity may allow us to control many aspects 
of cellular functions in disease. The next decade holds 
great promise for KAT research, as the recent techno-
logical advances in genomic, imaging and biochemical 
tools will allow us to systematically address questions 
that were previously unfeasible owing to technological 
constraints.
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